Organization
Janssen Research and Development LLC, Raritan, NJ
3 abstracts
Abstract
A phase 1 study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), and to determine the recommended phase 2 dose (RP2D) of subcutaneous (SC) cetrelimab (CET) in patients (pts) with advanced solid malignancies.Org: Medical Oncology, START Madrid-FJD, University Hospital Fundación Jiménez Diaz, Madrid, Spain, Gregorio Marañón University General Hospital, Madrid, Spain, Newcastle University, Newcastle upon Tyne, United Kingdom, Janssen Research & Development LLC, Titusville, NJ, Janssen (A Pharmaceutical Company of Johnson & Johnson), Montclair, NJ,
Abstract
Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition.Org: Memorial Sloan Kettering Cancer Center, Johns Hopkins University Bloomberg School of Public Health, Princess Margaret - University Health Network, University of Chicago Medical Center, Chicago, IL, United States Food and Drug Administration,
Abstract
Spatial genomics to reveal an immunosuppressive tumor microenvironment after chemoradiation in head and neck cancer patients.Org: Duke University Medical Center/Duke Cancer Institute, Genmab, Genmab Utrecht, Genmab US Inc., Janssen Research and Development LLC, Raritan, NJ,